FDA announces safety changes in labeling for some cholesterol-lowering drugs
Important safety changes to the labeling for some widely used cholesterol-lowering drugs known as statins are being announced today by the U.S. Food and Drug Administration.
These products, when used with diet and exercise, help to lower a persons bad cholesterol (low-density lipoprotein cholesterol). The products include: Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Combination products include: Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe).
We want health care professionals and patients to have the most current information on the risks of statins, but also to assure them that these medications continue to provide an important health benefit of lowering cholesterol, said Mary Parks, M.D., director for the Division of Metabolism and Endocrinology Products in the Office of Drug Evaluation II in FDAs Center for Drug Evaluation and Research.
The changes to the statin labels are:
* Certain cognitive (brain-related) effects have been reported with statin use. Statin labels will now include information about some patients experiencing memory loss and confusion. These reports generally have not been serious and the patients symptoms were reversed by stopping the statin. However, patients should still alert their health care professional if these symptoms occur.
The statins are responsible for much more than dementia/Alzheimer’s (which is slowly terminal in itself). My father died from Bayer Aspirin Company’s “Baycol” in 2002 at about 87. His kidneys were killed. He never suffered from dementia.